FDA Downgrades SMA Newborn Test to Class II
Published Date: 6/11/2026
Rule
Summary
The FDA is officially putting the Spinal Muscular Atrophy (SMA) newborn screening test into class II, meaning it has special safety rules but fewer hurdles than the strictest category. This change helps make the test safer and easier to get to babies who need it, starting June 11, 2026, with the classification effective since November 2022. Labs and device makers will benefit from clearer rules and faster access, helping catch SMA early without extra costs or delays.
Analyzed Economic Effects
5 provisions identified: 3 benefits, 2 costs, 0 mixed.
SMA Newborn Test Reclassified to Class II
The FDA classified the Spinal Muscular Atrophy (SMA) newborn screening test system as Class II (special controls), with the order effective June 11, 2026 and applicable since November 9, 2022. The agency says this classification provides reasonable assurance of safety and will enhance patients' access to the test.
Detailed Special-Control Study and Labeling Rules
To qualify under Class II, device makers must meet specified special controls, including extensive design verification and validation (detailed device description, analytical and clinical studies with summaries and 95% confidence intervals), multi-site reproducibility, lot-to-lot filter paper studies, reagent and shipping stability studies, software descriptions, and specific labeling statements (including that the test is prescription-only and presumptive positives require confirmatory diagnostic testing).
Lower Regulatory Hurdles for Test Makers
FDA says placing the SMA newborn screening test into Class II via the De Novo process reduces regulatory burdens and allows the device to serve as a predicate for future devices, which can speed market access for similar tests.
510(k) Premarket Submission Still Required
The order states that Spinal Muscular Atrophy newborn screening test systems are subject to premarket notification under section 510(k) of the FD&C Act at this time because FDA has not determined they should be exempt under section 510(m).
Prescription Screening; Positives Need Confirmation
The SMA newborn screening test system is identified as a prescription in vitro diagnostic intended to detect SMN1 gene deletions from dried blood spot specimens, and presumptive positive results are intended to be followed up by diagnostic confirmatory testing.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-15345, Food Safety Modernization Act Voluntary Qualified Importer Program User Fee Rate for Fiscal Year 2027
The Food and Drug Administration (FDA or we) is announcing the fiscal year (FY) 2027 annual fee rate for importers approved to participate in the Voluntary Qualified Importer Program (VQIP) that is authorized by the Federal Food, Drug, and Cosmetic Act (FD&C Act), as amended by the FDA Food Safety Modernization Act (FSMA). This fee is effective on August 1, 2026, and will remain in effect through September 30, 2027.
2026-15336, Food Safety Modernization Act Domestic and Foreign Facility Reinspection, Recall, and Importer Reinspection Fee Rates for Fiscal Year 2027
The Food and Drug Administration (FDA or we) is announcing the fiscal year (FY) 2027 fee rates for certain domestic and foreign facility reinspections, failures to comply with a recall order, and importer reinspections that are authorized by the Federal Food, Drug, and Cosmetic Act (FD&C Act), as amended by the FDA Food Safety Modernization Act (FSMA).
2026-15346, Biosimilar User Fee Rates for Fiscal Year 2027
Starting October 1, 2026, companies making biosimilar drugs will pay updated fees to the FDA for developing and getting approval for their products. These fees cover new drug development, application reviews, and yearly program costs. This helps the FDA keep biosimilar drug reviews speedy and fair while supporting innovation.
2026-15335, Medical Device User Fee Rates for Fiscal Year 2027
The Food and Drug Administration (FDA, Agency, or we) is announcing the fee rates and payment procedures for medical device user fees for fiscal year (FY) 2027. The Federal Food, Drug, and Cosmetic Act (FD&C Act), as amended by the Medical Device User Fee Amendments of 2022 (MDUFA V), authorizes FDA to collect user fees for certain medical device submissions and annual fees both for certain periodic reports and for establishments subject to registration. This notice establishes the fee rates for FY 2027, which apply from October 1, 2026, through September 30, 2027, and provides information on how the fees for FY 2027 were determined, the payment procedures you should follow, and how you may qualify for reduced small business fees.
Previous / Next Documents
Previous: 2026-11739, Medical Devices; Immunology and Microbiology Devices; Classification of the Simple Point-of-Care Device to Directly Detect SARS-CoV-2 Viral Targets From Clinical Specimens in Near-Patient Settings
The FDA is officially putting simple COVID-19 rapid test devices into a safer, easier-to-manage category called Class II. This change means these tests can get to patients faster and with fewer hoops to jump through, while still making sure they work well and stay safe. Starting June 11, 2026, companies making these tests will follow new rules that help speed up innovation without extra costs.
Next: 2026-11747, Safety Zones; Annual Events in the Captain of the Port Eastern Great Lakes Zone
The Coast Guard is setting up safety zones on the water for fun annual events in the Eastern Great Lakes this July 2026. Boat operators must follow rules and listen to Coast Guard directions during these times to keep everyone safe. These temporary zones might delay some boaters but won’t cost extra money.